Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

UFS researcher explores the future cost of cancer
2017-01-10

 Description: 001 Dr Alicia Sherriff Tags: 001 Dr Alicia Sherriff

Dr Alicia Sherriff, Head the Department of Oncology
at the UFS Faculty of Health Sciences, co-authored
an article in the South African Medical Journal.

Photo: Charl Devenish

Cancer is on an exponential rise globally, and the cost of treatment is a growing international problem. South Africa alone is expected to see a 78% increase in cancer cases. Dr Alicia Sheriff, Head of the Department of Oncology, collaborated on and co-authored a research paper for the South African Medical Journal on the future of oncology treatment in the country, along with doctors from various universities across South Africa. The article, titled "The future cost of cancer: interdisciplinary cost management strategy", looks at the prognosis of cancer management in the country.

Cancer is on the rise

There is a visible growth of the cancer disease in the developing world. Rapidly changing lifestyles, uncontrolled urbanisation, pollution, and population ageing are some dynamics that provide a lethal cocktail of infectious and lifestyle risk factors that leave people at a higher risk of developing cancer.

The simultaneous increase in cancer incidence has increased the cost of treatment exponentially. The cost of cancer treatment is multitiered, making the provision of care for cancer patients a high-risk business. A combination of treatment delays, limited resources, differently skilled personnel, high patient volumes and advanced disease stage on presentation all place a bigger burden on the delivery of optimal cancer care outcomes.

Adoption of new strategies

According to the doctors, innovative thinking to embrace technology, combined with a preventive approach, as well as lowering the cost of treatment drugs should be prioritised. So should the commercialisation of new technologies that will diagnose and treat cancer in its early stages. They also encourage interdisciplinary research funding in South Africa as a way to better understand the demographic and molecular dynamics of cancer in the country, along with retaining more oncologists in the public health sector.

Efficient solutions to curb cancer mortality

The doctors assert there is a need to continue to look for more efficient measures to best treat the disease, and hopefully bring about a change in mortality levels in South Africa.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept